The 90% seizure reduction post-treatment and extended half-life are strong efficacy signals that could position RAP-219 as best-in-class. With Phase 3 initiation imminent, traders should monitor upcoming trial designs and comparator arms for competitive positioning. Consider this a major value inflection ahead of potential FDA approval.
Price Chart
Executive Summary
Rapport Therapeutics announced positive follow-up data from its Phase 2a trial of RAP-219 in focal onset seizures, showing sustained efficacy with a 90% median reduction in clinical seizures during weeks 9-12 and a 59% reduction in weeks 13-16, alongside a newly estimated 22-day half-life. The drug was generally well tolerated, supporting advancement into two pivotal Phase 3 trials (FOCUS 1 and FOCUS 2) expected to start in Q2 2026.
Key Facts
- RAP-219 showed a 90% median reduction in clinical seizures during weeks 9-12 (follow-up period) and 59% reduction in weeks 13-16
- Drug's half-life revised upward to ~22 days from prior 14-day estimate, enabling sustained therapeutic levels
- Median reduction in long episodes (LEs) was 80% (weeks 9-12) and 68% (weeks 13-16)
- Two pivotal Phase 3 trials (FOCUS 1 and FOCUS 2) expected to initiate in Q2 2026
- Open-label extension (OLE) data expected in second half of 2026; Phase 2 bipolar mania results expected in first half of 2027
Financial Impact
High-value catalyst for a $1.8B market cap biotech; data support premium valuation and de-risk Phase 3 advancement
Risk Factors
- Phase 3 trials may not replicate Phase 2 results
- Regulatory hurdles for novel mechanism in epilepsy remain uncertain
- Insider selling of $1.2M over past 30 days may indicate profit-taking ahead of dilution
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3278481 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 2d ago | Insider Cluster | $26.00 | awaiting T+5 | — | $25.93 (−0.27%) |
Oct 22, 2026 4d ago | Insider Cluster | $27.33 | awaiting T+5 | — | $25.93 (−5.12%) |
Oct 21, 2026 4d ago | Insider Buy | $26.53 | awaiting T+5 | — | $25.93 (−2.26%) |
Oct 20, 2026 6d ago | 8-K | $29.37 | awaiting T+5 | — | $25.93 (−11.71%) |
Oct 6, 2026 19d ago | 144 | $30.86 $28.33 | ▲ +8.20% | ▲ +7.22% | $25.93 (+15.98%) |
Oct 1, 2026 24d ago | Insider Cluster | $32.17 $30.65 | ▼ −4.72% | ▼ −5.89% | $25.93 (−19.40%) |
Aug 26, 2026 8w ago | Insider Cluster | $50.83 $47.65 | ▼ −6.26% | ▼ −6.52% | $25.93 (−48.99%) |
Aug 5, 2026 11w ago | 8-K | $42.44 $47.73 | ▲ +12.46% | ▲ +12.11% | $25.93 (−38.90%) |
Jul 1, 2026 16w ago | Insider Cluster | $38.97 $41.75 | ▲ +7.13% | ▲ +5.77% | $25.93 (−33.46%) |
Jun 30, 2026 16w ago | 144 | $39.39 $39.72 | ▲ +0.84% | ▲ +0.58% | $25.93 (−34.17%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers